Assessing Zoetis (NYSE:ZTS) Valuation As Higher Value Pet Treatments Offset Softer Vet Visits

Conference spotlight and shifting demand in animal health

Zoetis (ZTS) is set to present at the 2026 KeyBanc Capital Markets Healthcare Virtual Forum on March 17, as investors assess how softer routine vet visits and higher-value treatments are shaping the animal health business.

See our latest analysis for Zoetis.

Despite resilient demand for higher-value treatments, Zoetis shares have been under pressure, with a 30 day share price return of 9.98% and a 1 year total shareholder return of 27.08%, suggesting momentum has been fading even as the business adapts to changing pet care spending.

If you are comparing Zoetis with opportunities in health related technology, this could be a good moment to scan the market through 36 healthcare AI stocks

With Zoetis shares down on a 1 year view despite revenue and net income growth, and trading below some valuation estimates, you need to ask: is this weakness a chance to enter, or is the market already pricing in future growth?

Most Popular Narrative: 23.2% Undervalued

Zoetis closed at $115.93, while the most followed narrative pegs fair value at $151.00 using a 6.98% discount rate, framing a sizeable valuation gap for investors to assess.

Significant growth potential is driven by unmet demand, market innovation, and leadership in key animal health segments, supporting recurring revenue and strong brand power. Expansion into emerging international markets and alternative sales channels diversifies revenue streams and sustains above-market growth while ongoing cost discipline improves margins.

Read the complete narrative.

Curious what kind of revenue profile and margin path could support that fair value, and what earnings multiple is built into the story? The narrative ties together growth, profitability and required returns in a way that might surprise you.

Result: Fair Value of $151.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, there are clear watchpoints, including execution risk around new osteoarthritis launches and growing competition in key franchises that could challenge the premium multiple story.

Find out about the key risks to this Zoetis narrative.

Next Steps

Mixed about what the market is signaling here? Take a moment to review the data, weigh both the concerns and the upside, and evaluate it in relation to 5 key rewards and 1 important warning sign.

Ready for more investment ideas?

If you stop with just one company, you risk missing opportunities that better fit your goals, so use the screener to line up your next few ideas confidently.

• Target potential mispricings by scanning companies that look out of favor but have quality traits through the 59 high quality undervalued stocks.
• Prioritize resilience by focusing on businesses with sturdy finances using the solid balance sheet and fundamentals stocks screener (39 results).
• Hunt for under-the-radar stories that the wider market may be overlooking with the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com